Ultralife (ULBI) to Announce Quarterly Earnings on Friday

Ultralife (NASDAQ:ULBI) is expected to be releasing its Q2 2026 results before the market opens on Friday, August 7th. Analysts expect Ultralife to post earnings of $0.19 per share and revenue of $55.00 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 7, 2026 at 8:00 AM ET.

Ultralife (NASDAQ:ULBI) last issued its earnings results on Friday, May 8th. The technology company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.18). The company had revenue of $47.45 million for the quarter, compared to analysts’ expectations of $52.40 million. Ultralife had a positive return on equity of 1.15% and a negative net margin of 4.37%.

Ultralife Trading Down 3.1%

NASDAQ ULBI opened at $5.31 on Thursday. The company’s 50-day simple moving average is $6.08 and its two-hundred day simple moving average is $6.34. Ultralife has a one year low of $4.90 and a one year high of $8.25. The company has a market capitalization of $88.46 million, a price-to-earnings ratio of -10.62 and a beta of 0.80. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.23 and a current ratio of 2.56.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut Ultralife from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Ultralife presently has an average rating of “Sell”.

Insider Transactions at Ultralife

In other Ultralife news, Director Bradford T. Whitmore acquired 67,302 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was acquired at an average cost of $6.81 per share, for a total transaction of $458,326.62. Following the purchase, the director owned 2,050,637 shares in the company, valued at approximately $13,964,837.97. The trade was a 3.39% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have purchased 108,878 shares of company stock worth $714,928. Company insiders own 42.90% of the company’s stock.

Hedge Funds Weigh In On Ultralife

Institutional investors have recently modified their holdings of the stock. XTX Topco Ltd lifted its holdings in Ultralife by 19.9% in the fourth quarter. XTX Topco Ltd now owns 15,456 shares of the technology company’s stock valued at $88,000 after acquiring an additional 2,569 shares during the period. Bank of America Corp DE boosted its holdings in Ultralife by 30.7% during the fourth quarter. Bank of America Corp DE now owns 12,067 shares of the technology company’s stock worth $90,000 after buying an additional 2,836 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in Ultralife by 1,650.0% during the second quarter. Lazard Asset Management LLC now owns 5,565 shares of the technology company’s stock worth $49,000 after buying an additional 5,247 shares in the last quarter. Empowered Funds LLC acquired a new stake in Ultralife during the fourth quarter valued at $44,000. Finally, Prelude Capital Management LLC purchased a new position in Ultralife in the third quarter valued at $71,000. Hedge funds and other institutional investors own 30.68% of the company’s stock.

About Ultralife

Ultralife Corporation (NASDAQ: ULBI) develops, manufactures and sells a broad range of energy and communications products for defense, medical, automotive and consumer electronics markets. The company operates through two primary segments: Power Systems and Communications Systems. In its Power Systems segment, Ultralife produces lithium-ion rechargeable cells and battery packs, primary lithium batteries, alkaline and rechargeable battery packs, chargers and battery accessories designed to meet demanding performance and safety requirements.